| Transformed Non-Hodgkin Lymphoma studied in …STUDIED_INderived75 of 75show fewer |
|---|
| → studied in | NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627245Phase 1 · active not recruiting Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665765Phase 2 · active not recruiting Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03380026Phase 2 · completed Mechlorethamine Induced Contact Dermatitis Avoidance Study · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04930653Phase 2 · recruiting Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784726Phase 2 · recruiting Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07365306Phase 2 · recruiting Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536049Phase 1/Phase 2 · recruiting Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03150329Phase 1 · active not recruiting Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03440567Phase 1 · completed Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06486051Phase 2 · recruiting A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03984448Phase 2/Phase 3 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05377827Phase 1 · suspended Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714421Phase 1 · not yet recruiting Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05828589Phase 1 · terminated A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04792489Phase 2 · recruiting DALY II USA/ MB-CART2019.1 for DLBCL · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05077527Phase 1 · recruiting Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672251Phase 2 · recruiting Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06015880Phase 1 · recruiting Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06854159Phase 2 · recruiting Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04850495Phase 1 · active not recruiting Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06905509Phase 2 · recruiting Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04257578Phase 1/Phase 2 · active not recruiting Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03277729Phase 1/Phase 2 · active not recruiting A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04545762Phase 1 · recruiting Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03321643Phase 1 · active not recruiting Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07220187Phase 3 · not yet recruiting Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638982Phase 1 · not yet recruiting Axatilimab + CAR-T for High-Risk Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06271057Phase 2 · recruiting Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05412290Phase 1 · active not recruiting Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06458439Phase 2 · recruiting Epcoritamab-CAR T Cells for Large B-cell Lymphomas · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04491370Phase 1/Phase 2 · recruiting Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04703686Phase 2 · completed Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05256641Phase 1/Phase 2 · recruiting Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07042438Phase 2 · recruiting Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05873712Phase 2 · recruiting Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04319237completed Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205838Phase 2 · terminated Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05755087Phase 1 · recruiting Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05432635Phase 1 · recruiting Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04067414Phase 1 · completed Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03749018Phase 2 · active not recruiting Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06834373Phase 2 · recruiting Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03210662Phase 2 · completed Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05890352Phase 2 · recruiting Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06343376Phase 1 · terminated Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03133221Phase 2 · completed 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06743945Phase 2 · recruiting POLA-R-CHP in the First-line Treatment of Transformed DLBCL · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04432506Phase 2 · completed Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04774068Phase 1 · completed Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05281809Phase 2 · recruiting Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02207062Phase 2 · completed Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04101331Phase 2 · completed Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05202782Phase 2 · active not recruiting Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06238648Phase 2 · recruiting Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02628405Phase 1/Phase 2 · unknown R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03892044Phase 1 · completed Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03103971Phase 1 · terminated huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06247540Phase 2 · withdrawn Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04220008Phase 2 · withdrawn Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04870853unknown Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01035463Phase 1/Phase 2 · completed Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03309878Phase 1/Phase 2 · completed Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05228249Phase 1 · withdrawn Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02572453Phase 2 · terminated Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL · condition mapped CURATED_BROADER · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03704714Phase 1/Phase 2 · suspended Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 75 trials mapped (43 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04058470Phase 1/Phase 2 · unknown Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03837873Phase 2 · unknown DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04476459Phase 1/Phase 2 · unknown Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04796857Phase 1/Phase 2 · unknown Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00225212Phase 2 · completed Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma · condition mapped ALIAS · 75 trials mapped (43 active) | — | — | Transformed Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |